RESULTS Direct conversion of hESC into GCs
hESC were cultured and expanded in the EpiLife medium. hESC displayed a cobblestone-like appearance (Fig. 1B, left). Immunostaining assays showed that cultured hESC expressed the epidermal stem cell markers cytokeratin 19 (CK19), CK14, CK5, 1-integrin, and proliferating marker Ki67 (fig. S1A). After differentiation induction with a high concentration of calcium, hESC flattened and expressed the differentiation markers transglutaminase 1 (TGase1) and loricrin (fig. S1B).
(A) Scheme of induction procedure. (B) Left: Microscope image of hESC. Scale bars, 100 m. Right: Morphological changes after chemical induction. Scale bars, 100 m (10) and 50 m (20). Arrow indicates the goblet-like cell. (C) Immunostaining of the MUC2 and E-cad in the induced cells. Nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI). (D) Immunostaining of the MUC2 and 1-integrin in the hESC control without chemical induction. (E) Immunostaining of the UEA-1. Arrow indicates mucus granules. (F to H) Immunostaining of the AGR2, TFF3, and RELM. (I) Western blotting of the control hESC and the RCBB-induced cells. (J) Percentage of MUC2-positive (MUC2+) cells in the induced total DAPI-positive cells after 7 days of chemical induction (means SEM). (K) Percentages of UEA-1-positive (UEA-1+) cells in the induced total DAPI-positive (DAPI+) cells at the indicated times (means SEM). (L) Immunostaining of UEA-1 in the induced cells from day 0 to day 6. (M to P) Immunostaining of the enterocyte marker CYP3A4 and villin, Paneth cell marker LYZ, and enteroendocrine cell marker ChrA. Scale bars, 25 m (C to H and L to P).
After plating in the collagen-coated plates or glass coverslips, hESC were induced by the chemical induction medium consisting of Dulbeccos modified Eagles medium (DMEM)/F12, 0.5% B27, 0.5% N2, 1% penicillin/streptomycin (P/S), 5 M Repsox, 3 M CHIR99021, bFGF (10 ng/ml), and BMP4 (10 ng/ml). The Repsox, CHIR99021, bFGF, and BMP4 were collectively named as RCBB (Fig. 1A). After 6 to 8 days of chemical induction, the cobblestone-like cell morphology was changed into small compact cells, with some cells displaying long, goblet-like morphology (Fig. 1B, right). These induced cells were immunopositive for the epithelial marker E-cadherin (E-cad) and GC marker MUC2 (Fig. 1C and fig. S2A). In contrast, the control hESC did not express the MUC2 (Fig. 1D). Western blotting confirmed the expression of MUC2 in the induced cells (Fig. 1I). The induced cells were also positive for the Ulex europaeus agglutinin-1 (UEA-1, detecting the GC product mucins), showing the presence of mucus granules in the cytoplasm (Fig. 1E, arrow). In addition, the induced cells expressed the GC products, such as anterior gradient protein 2 homolog (AGR2 or named as GOB4), intestinal trefoil factor 3 (TFF3), and resistin-like molecule (RELM) (Fig. 1, F to H). These results suggested that the induced cells are GCs, referred to as hESC-GCs. Quantification of MUC2-positive cells showed that 94.98 1.28% of cells were positive for MUC2 at day 7 after induction (Fig. 1J). We further calculated the induction efficiency from day 1 to day 6 by measuring the percentages of the UEA-1positive cells relative to the total 4,6-diamidino-2-phenylindole (DAPI)positive cells after chemical induction. A gradual increase in the number of hESC-GCs was observed during the chemical induction (Fig. 1, K and L). hESC-GCs were negative for markers of other types of intestinal cells, such as the enterocyte markers (CYP3A4 and villin), Paneth cell marker [lysozyme (LYZ)], and enteroendocrine cell marker [chromogranin A (ChrA)] (Fig. 1, M to P). Moreover, the epithelial columnar cell markers CK8/CK18 and CK19 and the epithelial marker, epithelial cell adhesion molecule (EpCAM), were expressed in the hESC-GCs (fig. S2, B to E). Zonula occludens-1 (ZO1) and occludin, the tight junction proteins, were detected around the hESC-GCs (fig. S2, F and G). Western blotting verified that hESC-GCs expressed the epithelial markers and did not express villin, ChrA, and LYZ (fig. S2M). hESC-GCs could proliferate in the induction medium, as evidenced by the Ki67 staining and cell counting kit-8 (CCK-8) assay (fig. S2, H and I).
hESC and hESC-GCs both expressed the transcription factor GATA6 (GATA-binding factor 6) and KLF4 (Kruppel-like factor 4) (fig. S2, J, L, and M), which may facilitate the direct conversion because GATA6 and KLF4 are necessary for GC differentiation (11, 12). GATA 6 expression is restricted to the distal colon epithelial cells (12, 13). However, hESC-GCs did not express GATA4 (fig. S2, K and M), which is generally expressed in the proximal intestine (13, 14). These results implied that hESC-GCs may be distal colon GCs.
As GCs secrete neutral and acidic mucins, we performed periodic acidSchiff (PAS) staining detecting both neutral and acidic mucins. hESC-GCs were positive for PAS staining (Fig. 2A, left). We further performed Alcian blue (AB) staining to detect acidic mucins specifically. Figure 2A (middle) shows that hESC-GCs were AB positive. AB-PAS staining proved to be positive for both AB and PAS staining (Fig. 2A, right). By contrast, control hESC were negative for PAS and AB staining (Fig. 2A, bottom). Transmission electron microscopy revealed that almost all hESC-GCs have an apical part distended with large rounded mucus globules of moderate electron density and a basal part containing the nucleus (Fig. 2B and fig. S3). There were few microvilli on the hESC-GCs. hESC-GCs were enriched with mitochondria and endoplasmic reticulum in the cytoplasm (fig. S3). The mucus secretion properties further supported the chemical conversion of hESC into GCs.
(A) PAS, AB, and AB-PAS staining of hESC-GCs and control hESC. (B) Transmission electron micrograph of hESC-GCs. Almost all the hESC-GCs have large rounded mucus globules (MG) of moderate electron density and a basal part containing the nucleus (N) [top (1500, 2 m) and bottom (3000, 1 m)]. (C) RT-qPCR analysis of relative mRNA expression levels of mucus-associated genes MUC2, RELM, FCGBP, ZG16, TFF3, and AGR2 and GC fate commitment and differentiation-associated genes ATHO1 and SPDEF in hESC-GCs and control hESC. Values are presented as means SEM (n = 3; ***P < 0.001, ****P < 0.0005 versus control group). (D) ALI culture, representative images of mucus secretion after 2 and 7 days of ALI culture in a six-well plate, respectively. Right: Tubes collecting the mucus. Photo credit: Andong Zhao, PLA General Hospital. (E and F) Representative images showing PAS and AB staining of hESC-GCs cultured in the ALI system. (G and H) Representative images of E-cad, MUC2, and CK18 in hESC-GCs cultured in the ALI system. Scale bars, 100 m (A), 50 m (E and F), and 25 m (G and H).
We then performed real-time quantitative polymerase chain reaction (RT-qPCR) analysis of GC-associated genes in hESC-GCs. hESC-GCs increased the mRNA expression of MUC2 and other GC products such as RELM, Fc- binding protein (FCGBP), and zymogen granule protein 16 (ZG16), AGR2, and TFF3, as compared to control hESC group (Fig. 2C). hESC-GCs also up-regulated the gene expression of the transcription factor ATOH1 (protein atonal homolog 1) and SPDEF (SAM pointed domain-containing Ets transcription factor), which are essential for the differentiation of intestinal secretory lineage cells (Fig. 2C). These results suggested that hESC-GCs acquire the key gene expression phenotypes of GCs.
To determine the effects of the small molecules and growth factors, we tested different combinations of them. Treatment with single Repsox (R), bFGF, and BMP4 failed to induce hESC into cells positive for PAS and AB staining (fig. S4, B to D). However, CHIR99021 (C) treatment could induce hESC into PAS- and AB-positive cells (fig. S4E). The addition of Repsox into CHIR99021 could accelerate the morphological changes of hESC into GCs (fig. S4F). bFGF and BMP4 were able to increase the morphological changes and efficiency of conversion (fig. S4, G and H). These data implied that CHIR99021, an inhibitor of glycogen synthase kinase 3 beta (GSK-3), may play a critical role in GC induction by activation of Wnt signaling. Accordingly, we tested whether another GSK-3 inhibitor could substitute CHIR99021 and found that Kenpaullone (K), another GSK-3 inhibitor, could also induce hESC into GCs (RKBB; fig. S5A). It is well known that Wnt activation or GSK-3 inhibition promotes the nuclear translocation of the downstream -catenin and transcriptional activation of the Wnt target genes. Immunostaining showed that CHIR99021, RCBB, or RCBMP4 treatment resulted in nuclear translocation of -catenin, not Repsox (fig. S6A).
Wnt activation is associated with the phosphorylation status of GSK-3 because GSK-3 can phosphorylate -catenin and promote the degradation of -catenin. Inhibitory phosphorylation of GSK-3 at Ser9 can inhibit the kinase activity of GSK-3. CHIR99021 is known to inhibit GSK-3 kinase activity by competing the adenosine 5-triphosphate (ATP)binding domains and blocking the transfer of the terminal phosphate from ATP to the protein substrate. As a result, CHIR99021 can block phosphorylation of every GSK-3targeted substrate including -catenin, which increases the stability and accumulation of -catenin in cytosol and nucleus. Nevertheless, we explored whether RCBB activates Wnt signaling via altering the inhibitory phosphorylation of GSK-3 at Ser9 (p-Ser9 GSK-3). Western blotting revealed that RCBB treatment did not increase the level of p-Ser9 GSK-3 (fig. S6, B and C), indicating that CHIR99021 inhibits activity of GSK-3 not by increasing the inhibitory phosphorylation levels of GSK-3. A decrease in the ratio of p-Ser9 GSK-3 versus GSK-3 was detected during the initial chemical induction (fig. S6, B and C). Mechanistically, CHIR99021 inhibits GSK-3 activity regardless of its phosphorylation status. Therefore, CHIR99021 can still activate the Wnt signaling. qPCR analysis showed that RCBB treatment led to an increase in the mRNA levels of Wnt/-catenin downstream genes T cell factor 1 (TCF1) and lymphoid enhancer factor (LEF1) and a slight decrease in the mRNA levels of TCF3, TCF4, GSK-3, and -catenin as compared to the control hESC (fig. S6D). A single CHIR99021 also up-regulated the TCF1 and LEF1 and slightly increased GSK-3 in the hESC after 3 days of treatment (fig. S6E). However, 3-day treatment with RCBB down-regulated the GSK-3 (fig. S6F), indicating that Repsox, bFGF, and BMP4 also partially affected the GSK-3. The other two inhibitors of transforming growth factor (TGF-) signaling, A83-01 and SB431542, could substitute Repsox for generating GCs (fig. S5, B and C).
Notch signaling inhibits GC differentiation in the intestine (15). We determined whether DAPT, an inhibitor of the Notch signaling pathway, could promote the conversion of hESC into GCs. When added into RCBB or RC, DAPT seemed to promote the morphological changes into long goblet-like shape (fig. S7).
hESC-GCs were seeded onto Transwell systems and grown to confluence, and then the medium was removed in the upper chamber of the Transwell, constituting the transition to air-liquid interface (ALI) culture condition. After 1 to 2 days in the ALI culture system, hESC-GCs began to secrete mucus (Fig. 2D). Within 7 days, cells in the six-well Transwell could secrete 50 to 100 l per well, as shown in Fig. 2D and movie S1. Cells on the Transwell membrane were strongly stained for PAS and AB (Fig. 2, E and F), indicating enrichment of mucins after ALI culture. Immunostaining assay showed that cells cultured in ALI retained expression of epithelial marker E-cad and GC marker MUC2 and CK18 (Fig. 2, F and G).
Massive secretion of MUC2 mucin by exocytosis is triggered by a wide array of bioactive factors, including cholinergic agonists, hormones, microbes, and microbial products, and inflammatory cytokines. We analyzed the responses of hESC-GCs to these mucin secretagogue signals.
As the cholinergic agonist can stimulate mucus secretion from GCs (4, 5), we treated hESC-GCs with 1 mM cholinergic agent carbachol (CCh) for 2 hours and found that CCh increased the MUC2 mRNA and protein expression levels as compared to the control group (Fig. 3, A and C). Moreover, CCh treatment led to increased secretion of mucin to the culture medium (Fig. 3B). These results suggested that hESC-GCs were able to respond to cholinergic agonists. Activation of Toll-like receptor 2 (TLR2) can stimulate mucus secretion (1). The synthetic Pam3CysSK4 (PCSK), a TLR2 ligand, has been reported to stimulate mucus secretion from GCs. After treatment with PCSK (20 g/ml), hESC-GCs for 2 hours increased the mucin secretion from hESC-GCs, which was reported in a previous study (Fig. 3, A, B, and D) (6). Lipopolysaccharide (LPS) from Gram-negative and Gram-positive bacteria, another TLR2 ligand, is known to induce mucus production (16). The addition of LPS to hESC-GCs for 24 hours increased the mRNA expression of MUC2, RELM, and FCGBP (Fig. 3E). T helper cell 2 (TH2) cytokine interleukin-13 (IL-13) was demonstrated to regulate mucin production (16, 17). In our study, IL-13 treatment for 1 and 3 days led to an increase in the mRNA expression of MUC2, FCGBP, and SPDEF and a decrease in the mRNA expression of RELM (Fig. 3F). The decrease in the RELM mRNA expression induced by IL-13 treatment contrasted with the increased RELM in LS174T cells after IL-13 treatment (16). Future works should be used to study why hESC-GCs reduced the RELM mRNA expression after IL-13 treatment.
(A and B) PAS assay for measuring MUC2 content in cell lysates and culture media after CCh and PCSK treatment, respectively. Values are presented as means SEM (n = 3; **P < 0.01, ****P < 0.0005 versus control group). (C and D) Relative MUC2 mRNA expression in hESC-GCs after CCh and PCSK treatment. Values are presented as means SEM (n = 3 versus control group). (E and F) Treatment with LPS for 24 hours or interleukin-13 (IL-13) for 1 and 3 days led to changes in the mRNA levels of MUC2, RELM, FCGBP, and SPDEF. Values are presented as means SEM (n = 3; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0005, versus control group).
GCs have been demonstrated to deliver antigen from the intestinal lumen to the antigen-presenting cells, the lamina propria dendritic cells, via GAPs (4, 5). We treated the cultured enhanced green fluorescent protein (EGFP)positive hESC-GCs with cell membraneimpermeable model antigen rhodamine B labeled dextran (RB-dextran) (10 kDa) for 2 hours. Fluorescent images showed that RB-dextran granules were present in the cytoplasm of EGFP-positive GCs and were close to the Hoechst 33342positive nucleus, indicating that hESC-GCs could take up the fluorescent antigen (Fig. 4A and fig. S8A). GCs in the small intestine and colon could form GAPs (fig. S8B) (4, 5). We transplanted EGFP-positive hESC-GCs into the intestine and colon of mice and found that EGFP-positive hESC-GCs could attach the small intestinal epithelia and take up the RB-dextran in vivo, evidenced by EGFP-positive epithelial cells containing a DAPI nucleus and dextran, which indicated the GAP formation (Fig. 4B and fig. S8C, white squares and red arrowheads). We also found that hESC-GCs could attach the colon epithelia and take up RB-dextran (fig. S8D). We further cocultured EGFP-positive hESC-GCs with dendritic cells and found that EGFP-positive hESC-GCs could take up more RB-dextran than dendritic cells (Fig. 4C). These results indicated that hESC-GCs may take up fluorescent antigens and possibly form GAPs.
(A) Fluorescent images of RB-dextran and EGFP in the hESC-GCs after incubation with RB-dextran. (B) Fluorescent images of RB-dextran and EGFP in the small intestines of mice receiving transplantation of EGFP-positive hESC-GCs and injection of RB-dextran. White squares and arrows indicating the GAP formation. (C) Fluorescent images of RB-dextran and EGFP in cocultured EGFP-positive hESC-GCs and EGFP-negative human dendritic cells. (D to F) RT-qPCR for the mRNA expression of mAChR4, EGFR, and MYD88 signaling components in the hESC-GCs and hESC. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. (G and H) Western blotting of hESC-GCs and hESC-GCs infected with enteroinvasive (EIEC) E. coli (hESC-GCs EIEC). p-EGFR, phosphorylated EGFR. (I) Quantification of Western blotting analysis of hESC-GCs and hESC-GCs EIEC. The expression level of p-EGFR and mAChR4 in hESC-GCs EIEC was normalized to that of the control hESC-GCs. *P < 0.05. (J) Immunostaining of p-EGFR, mAChR4, and MYD88 in hESC-GCs and hESC-GCs EIEC. (K) RT-qPCR analysis of the mRNA expression of EGFR and mAChR4 in hESC-GCs EIEC and hESC-GCs (means SEM, n = 3). (L) RT-qPCR analysis of the mRNA expression of TLR2, TLR4, and TLR5 and MYD88 in hESC-GCs EIEC (means SEM, *P < 0.05 versus control hESC-GCs). Scale bars, 25 m (A to C and J).
Knoop et al. (5) has also demonstrated that acetylcholine can induce GAP formation by acting on muscarinic Ach receptor 4 (mAChR4) expressed by GCs and that activation of epidermal growth factor receptor (EGFR) can inhibit GAP formation. We found that both hESC and hESC-GCs expressed messenger RNAs for the mAChR4 and EGFR (Fig. 4, D and E). Immunocytochemistry analyses demonstrated the expression of mAChR4 on hESC and hESC-GCs, but many mAChR4 were in the cytoplasm, not on the cell membrane (Fig. 4J). Although bacterial infection did not significantly change the expression level of mAChR4 in hESC-GCs (Fig. 4, H, I, and K), more mAChR4 were located on the cell membrane (Fig. 4J). Activation of EGFR [phosphorylated EGFR (p-EGFR)] was detected in hESC-GCs, and bacterial infection led to an increased activation of EGFR (Fig. 4, G and I).
Because GC-intrinsic myeloid differentiation primary response (MYD88)dependent microbial sensing can activate EGFR and inhibit GAP formation (5), we evaluated the MYD88 signaling components in hESC-GCs and hESC. RT-qPCR showed that hESC-GCs and hESC expressed TLR1, TLR2, TLR3, TLR4, and TLR5, with hESC-GCs expressing slightly higher levels of TLR1, TLR4, and TLR5 (Fig. 4F). In addition, hESC-GC expressed the mRNAs of MYD88 and other MYD88 signaling components tnf receptor associated factor 6 (TRAF6), interleukin 1 receptor associated kinase 4 (IRAK4), nuclear factor B (NF-B), and interferon alpha 1 (IFNA1) (Fig. 4F). Immunostaining assays verified the presence of MYD88 in the cytoplasm of hESC-GCs and hESC (Fig. 4J and fig. S8E). Bacterial infection increased MYD88 in the hESC-GCs (Fig. 4J), which is consistent with the increased activation of EGFR. Moreover, bacterial infections increased the expression of RELM (Fig. 4J, right). Together, these above results indicated that hESC-GCs could deliver fluorescent antigens.
We compared the adherence of E. coli strains to HeLa cells (a conventional immortalized cell line used currently for this assay) and hESC-GCs. We performed the adherence assays using wild-type strains with enteropathogenic (EPEC), enteroinvasive (EIEC), enterohemorrhagic (EHEC), and enterotoxigenic (ETEC) E. coli. These strains adhered robustly to hESC-GCs cultured in monolayers, like HeLa cells (Fig. 5A). These visual observations suggested the adherence of E. coli to hESC-GCs.
(A) hESC-GCs and HeLa cultured in monolayers were incubated with the indicated E. coli strains, assessed by crystal violet staining. (B and C) Representative images of hESC-GCs cultured in cell mass and infected with the indicated E. coli strains. Clustered hESC-GCs formed circular mucus droplets [top (10) and bottom (20)]. High-power images (C). (D) hESC-GCs were cultured in the upper chamber of the Transwell system, and bacteria were added in the lower chamber. After 3 to 4 days, a viscoelastic, gel-like mucus layer was formed. Photo credit: Andong Zhao, PLA General Hospital. PAS, AB, crystal violet, and UEA-1 staining of the gel. (E) hESC-GCs cultured in HCM formed viscoelastic mucus. Left: Appearance of the thin, transparent gel after fixation of the mucus. Right: PAS, AB, AB-PAS, and UEA-1 staining of the gel. (F) hESC-GCs cultured in HCM and infected with EIEC formed viscoelastic mucus. Left: Appearance of the thick, opaque gel after fixation of the mucus. Right: PAS, AB, AB-PAS, and UEA-staining of the gel. The lower panels showed the costaining of AB, PAS, and crystal violet in the gel. Scale bars, 100 m (A to F).
When we cultured the hESC-GCs in cell mass and infected the cell mass with E. coli strains for 1 to 2 days, we observed an interesting phenomenon. The clustered hESC-GCs could secrete mucus and form many small, circular, bright mucus droplets surrounding the edge of the cell mass, and the droplet barriers could largely separate bacteria from the cell mass (Fig. 5B). The mucus droplets could retain their shapes for several days, and bacteria could not destroy the droplet barriers. We could only observe few bacteria in the droplets (Fig. 5C and movie S2). However, circular mucus droplets were not easily observed when hESC-GCs were cultured in monolayers with the presence of E. coli. The difference might indicate that enough number of hESC-GCs was required to secrete high levels of mucins and form mucus droplets. The mucus droplets may function as like the inner mucus layer in colon, which is impervious for bacteria and separates bacteria from the colon epithelia (18). This led to the hypothesis that intestinal GCs first secrete mucins to form mucus droplets, and then many layers of droplets constitute the inner mucus layers, which may explain the mechanisms of forming inner mucus layer in colon.
GCs can secrete mucins to form a mucus layer that provides the frontline host defense against endogenous and exogenous irritants and a good habitat for microbial colonization because oligosaccharides of MUC2 offer numerous microbial attachment sites and energy source (1). However, it is hard to study the microbial community residing in the mucus layer across the length of the intestinal tract, given the difficulty to sample this region in vivo, especially in humans. We developed cellular models to study the spatial organization of the gut microbial ecosystem. We cultured hESC-GCs in the upper chamber in the Transwell system. In the lower chamber, bacteria were added into the culture medium, and the upper chamber was filled with bacteria-free medium. After 3 to 4 days, a viscoelastic, gel-like mucus layer was formed in the lower chamber (Fig. 5D, fig. S9A, and movie S3). However, the mucus layer could not form without bacteria in the lower chamber (fig. S9B). Apparent microbial colonization was observed in the mucus layer, with much higher bacteria in the mucus layer than in the culture medium (fig. S9C). In particular, bacteria were trapped and fixed in the mucus layer right under the upper chamber (fig. S9C). After fixation with Carnoys solution, the mucin gel formed in the Transwell system was positive for AB and PAS staining, and the bacteria were positive for crystal violet staining (Fig. 5D). The mucus layer could be stained by the lectin UEA-1 (Fig. 5D). We developed another indirect culture system by culturing hESC-GCs on the 24-well plates and covering the cells with glass coverslips on the top. Bacteria were then added to the culture. Three to 4 days after coculture, a big, complex gel-like mucus layer was formed in the medium (fig. S9D). Likewise, the gel-like layers were colonized by bacteria and positive for PAS, AB, crystal violet staining, and UEA-1 immunofluorescent staining (fig. S9D). This phenomenon indicated that microbes could spontaneously stimulate the hESC-GCs to secrete mucins and form a gel-like mucus layer for bacterial colonization.
We then investigate whether hESC-GCs could secrete mucin to form gel-like mucus without the bacterial infection. We replaced the DMEM/F12-based medium with HCM (hepatocyte culture medium) and cultured the hESC-GCs in a Transwell system or 24-well or 6-well plates and found that hESC-GCs could secrete mucins to form viscoelastic, gel-like mucus for 2 to 3 days of culture. When the gel-like mucus was fixed with Carnoys solution, thin, transparent, gel-like networks were observed (Fig. 5E, left). The gel-like networks were positive for AB and PAS staining and UEA-1 immunostaining (Fig. 5E). When hESC-GCs were cultured in HCM and in the presence of E. coli, the formed gel-like mucus was thicker after fixation (Fig. 5F, left). The thick gel-like layers were positive for AB and PAS staining and UEA-1 staining (Fig. 5F). The gel-like networks were colonized by many bacteria, observed by crystal violet staining (Fig. 5F). These results suggest that hESC-GCs can spontaneously form gel-like mucus colonized by bacteria after bacterial infection, recapitulating the intestinal outer mucus layer.
We next tested the transplantation of the cultured hESC-GCs. We induced acute colonic mucus damage in immunodeficient NOD-SCID IL2rg/ (NSG) mice with colitis-inducing dextran sulfate sodium (DSS) for 5 days (Fig. 6A, right). Most of the mice developed acute colitis characterized by weight loss, bloody stool, diarrhea, and epithelial injury in the distal colon. At 7 and 10 days after DSS administration, we dissociated EGFP-positive hESC-GCs into small fragments (Fig. 6B), suspended them in a Matrigel-containing phosphate-buffered saline (PBS), and instilled them in recipient mice. After 3 hours of transplantation, EGFP-positive cells attached to the luminal surface (Fig. 6C). After 7 days of cell transplantation, recipient mice were euthanized, and the recipient colons showed varying degrees of recovery (Fig. 6A, right). Multiple EGFP-positive areas appeared as well-demarcated patches in the treated distal colons (Fig. 6D). The transplanted hESC-GCs were adapted to the colonic tissue, and mucin gel was observed around the hESC-GCs (Fig. 6D). The transplanted EGFP-positive cells were immunopositive for GC marker MUC2 (Fig. 6E). Hematoxylin and eosin (H&E) staining showed that transplantation of hESC-GCs promotes the repair of the mucus layer and intestinal epithelia in the acute colitis model (Fig. 6F). Notably, many transplanted EGFP-positive hESC-GCs adhered to the outer mucus layer and died or were removed out with feces soon. Only a small number of transplanted hESC-GCs could attach the ulcerated sites of colons. Therefore, increasing the survival and decreasing the removal of hESC-GCs through feces are important for transplantation therapy.
(A) The right panel displayed the recipient colon at 7 days after the initiation of DSS administration, and the left panel displayed the recipient colon at 7 days after cell transplantation (n = 10). (B) Representative fluorescent images of EGFP-positive hESC-GCs. (C) Representative fluorescent image of EGFP-positive hESC-GCs areas attaching the mucosal layer in the distal colon at 3 hours after transplantation. (D) Representative fluorescent images of EGFP-positive hESC-GC areas overlapping the damaged region after 7 days of transplantation. (E) Representative images showed that EGFP-positive transplanted area was immunopositive for MUC2. (F) H&E staining of distal colon sections in acute colitis mice and in colitis-induced mice transplanted with hESC-GCs after 7 days of cell transplantation. (G to I) H&E, AB-PAS, and UEA-1 staining of colon sections in acute colitisinduced mice treated with chemical culture media containing RCBB (Chemical, n = 8) and control basal media without RCBB (Control, n = 8) after 14 days of oral administration. Scale bars, 25 m (E), 100 m (G to I).
We further investigated whether oral administration of the chemical culture medium containing RCBB could promote the colon epithelial regeneration after acute damage. The administration of DSS for 7 days led acute damage to colon epithelia in the adult C57BL/6 mice, and then the drinking water was replaced with the chemical culture medium in the experimental group, and the control group was administered with the basal culture medium without the chemical compounds. After 14 days of oral administration, mice were euthanized, and histological analysis revealed that chemical culture medium enhanced the regeneration of colon epithelia in the experimental group, with thicker epithelial layers as compared to the control group (Fig. 6G). AB-PAS staining showed more GCs in the injured colon epithelial sites after oral administration of chemical culture media as compared to control media (Fig. 6H). Immunostaining analysis revealed that more UEA-1positive mucus granules were present in the injured epithelia of chemical culture medium group than those observed in the control group (Fig. 6I). These results suggest that chemical culture medium promotes the recovery of the injured intestinal epithelia.
We further investigated the effects of the chemical treatment on the differentiation of adult mouse intestinal organoids (or ISC) in vitro. Mouse small intestinal crypts were embedded in Matrigel and cultured in the presence of growth factors including EGF, Noggin, and R-spondin 1 (ENR). Under the ENR condition, intestinal organoids developed many crypt-villus structures (fig. S10A). After 4 days of culture in the ENR condition, passaged intestinal organoids were then cultured in the ENR condition plus the RCBB cocktail for another 4 days. We found that RCBB decreased the proliferation of crypt cells, as evidenced by decreased numbers of crypt buds and Ki67-positive cells and reduced size of organoids compared to those observed with ENR cultures (fig. S10, A and H). We then compared the differentiation of intestinal organoids cultured in different conditions. Intestinal organoids could spontaneously differentiate into alkaline phosphatasepositive and CYP3A4-positive enterocytes (fig. S10, B and D), PAS-positive and MUC2-positive GCs (fig. S10, C and E), LYZ-positive Paneth cells (fig. S10F), and ChrA-positive enteroendocrine cells (fig. S10G), which were consistent with previous reports (8, 19, 20). Intestinal organoids cultured in the ENR + RCBB condition also could differentiate into the four types of intestinal epithelial cells (fig. S10, B to G). However, RCBB increased the GC differentiation as compared to the ENR condition (fig. S10, C and E). These results suggest that RCBB may promote the differentiation of mouse intestinal organoids into intestinal epithelial cells, especially GCs.
The intestinal mucus layer secreted by GCs provides the first line of defense against injury caused by digested food, microbes, and microbial products. Moreover, GCs contribute to mucosal immune responses by secreting antimicrobial proteins, chemokines, and cytokines and forming GAPs (46). The dysfunction of GCs has been associated with multiple diseases, including inflammatory bowel disease and cystic fibrosis, indicating that GCs are not always innocent bystanders and can be active participants in disease pathogenesis (1, 21). However, it is challenging to independently investigate the functions of GCs because of the difficulty in isolating GCs from intestinal epithelial cells. Recent studies have reported to differentiate ISC or pluripotent stem cells into intestinal epithelial cells, including enterocytes, GCs, Paneth cells, and enteroendocrine cells (8, 9, 22). However, those differentiation procedures involve complex, long-time procedures, a combination of various growth factors, and a three-dimensional culture system. Moreover, only a small subset of GCs was obtained within the induced intestinal epithelial cell types. In our study, we have induced a homogeneous population of GCs from hESC with a simple, rapid method. The induction process requires 6 to 8 days of chemical induction, without three-dimensional culture systems. The two small molecules used are cost effective and easy to be synthesized. Compared to ISC or PSC, hESC is relatively easier to obtain from the skins.
Because the direct conversion of hESC into GCs was rapid, we investigated the molecular mechanisms by which hESC are induced into GCs. Wnt signaling is an important signaling pathway for regulating the GC differentiation in the intestine (23, 24). Inhibition of Wnt signaling in the intestine resulted in a remarkable reduction in the secretory cells including GCs, enteroendocrine cells, and Paneth cells (23). Activation of Wnt signaling could promote GC differentiation in the intestinal organoid development (25). In addition, activation of Wnt signaling with GSK-3 inhibitor 6-bromoindirubin-3-oxime (BIO) could induce differentiation of human ES into all four intestinal differentiated cell types including GCs (10). The transcription factor SPDEF, a critical regulator for GC differentiation, maturation, and function, was found a downstream target of Wnt signaling in the intestine (26). Consistent with these results, activation of Wnt signaling by CHIR99021 used in the study played a critical role in the GC induction from hESC (fig. S4). CHIR99021 is a GSK-3 inhibitor by competing the ATP-binding domain of GSK-3, which can inhibit the GSK-3mediated phosphorylation of every substrate (27). Activation of Wnt after chemical induction was observed, evidenced by increased accumulation and nuclear translocation of -catenin and up-regulation of Wnt signaling downstream genes (fig. S6, A and D). Inhibitory phosphorylation of GSK-3 can reduce the phosphorylation and degradation of -catenin, thereby activating the Wnt signaling (28). RCBB did not increase the inhibitory phosphorylation level of GSK-3 (p-Ser9 GSK-3) during the initial stage of chemical induction (fig. S6, B and C), suggesting that RCBB activated the Wnt signaling not by increasing the inhibitory phosphorylation of GSK-3. Wnt activation by RCBB treatment likely depended on the CHIR99021 blocking of the ATP-binding domain in GSK-3 and subsequent inhibition of its kinase activity (27, 29). Single CHIR99021 treatment increased the mRNA expression of GSK-3 slightly after 3 days of treatment (fig. S6E). It was possible that inhibition of GSK-3 kinase activity by single CHIR99021 would slightly stimulate the expression of GSK-3 in hESC and compensate the loss of GSK-3 activity. However, RCBB treatment would reduce the increase in the mRNA expression of GSK-3 observed in the treatment with single CHIR99021 (fig. S6F), indicating that Repsox, bFGF, and BMP4 also affected the mRNA expression of GSK-3.
TGF- signaling pathway is another important pathway involved in GC differentiation. TGF- signaling was found to restrict the GC differentiation in the conjunctiva by inhibiting the expression of SPDEF in a Smad3-dependent manner (30). In the intestine, depletion of either Smad3 or Smad4, the downstream mediators of TGF- signaling pathway, resulted in gastric and duodenal mucinous adenocarcinoma that were characterized by an abundance of GCs (31, 32). In the airway epithelia, activation of Smad signaling also restricted the GC differentiation (33). These results collectively suggested that TGF- signaling play a global role in restricting the GC differentiation (30). Therefore, the inhibitors of TGF- signaling, such as Repsox, SB431542, and A83-01, promoted the GC induction from hESC in the present study (fig. S5). bFGF has been used to induce definitive endoderm into the gut lineage cells (34). bFGF and BMP4 were shown to act synergistically with BIO and DAPT to enhance the differentiation of human ES into the intestinal epithelium including GCs (10). Notch signaling pathway suppresses the GC differentiation from ISC (15). The addition of the Notch pathway inhibitor DAPT could increase the maturation of hESC-GCs (fig. S7), but was dispensable for GC induction from hESC.
KLF4 is required for the terminal differentiation of GCs in the intestine (11). The expression of KLF4 is present both in the hESC and hESC-GCs (fig. S2M), which may, in part, explain why hESC can be easily converted into GCs. GCs have distinct functions in different segments of the intestine. GATA6 is required for normal maturation of GCs in the colon, whereas, in the small intestine, GATA6 does not play a role in commitment, differentiation, or maturation of GCs (1214). However, GATA4 is expressed in the proximal small intestines and absent in the distal colons (14). Consistent with these results, we found that hESC-GCs expressed GATA6 but not GATA4, indicating that hESC-GCs might be restricted to colons. However, more study will be needed to determine whether the induced hESC-GCs belong to small intestines or colons, such as comparing the global gene expression profiles of hESC-GCs with those of human GCs in the small intestines and colons.
hESC-GCs were functional because hESC-GCs could secrete mucins and respond to several mucin secretagogue signals. Cholinergic agent (CCh) has been widely used to induce secretion of GCs (4, 5), which was consistent with increased secretion in hESC-GCs after CCh treatment. Activation of TLR2 can stimulate mucus secretion in GCs (1, 21). The TLR2 ligand PCSK increased mucus secretion from hESC-GCs, in accordance with previous study (35). Bacterial infection is the major factor inducing GC secretion (1). Treatment with LPS resulted in increased mucus secretion from hESC-GCs. TH2-mediated immune responses also regulate the GC secretion. TH2 cytokines, IL-4, and IL-13, induced by nematode infection, could increase the mucus secretion and cause expulsion of parasites (17). Although IL-13 treatment induced the mRNA expression of MUC2, FCGBP, and SPDEF, IL-13 resulted in decrease in the mRNA of RELM, which was up-regulated in intestinal GCs after parasite infection and LS174T cells after IL-13 treatment (16, 17, 36). Why hESC-GCs down-regulate RELM in response to IL-13 remains to be studied in the future.
GCs can form GAPs and deliver luminal substances to antigen-presenting cells in the lamina propria, inducing adaptive immune responses (4, 5, 3739). The GAPs can be identified by using the ability of GCs to take up fluorescently labeled dextran (fig. S8B). After exposure to fluorescent RB-dextran in vitro, hESC-GCs actively took up the dextran into their cytoplasm (Fig. 4A). However, the in vitro uptake experiment did not demonstrate the GAP formation in vivo because of the in vitro culture environment. After transplantation of EGFP-positive hESC-GCs into the small intestine and colon, EGFP-positive hESC-GCs attached the small intestine and colon and transcellularly took up the fluorescent dextran, manifested by EGFP-positive epithelial cells containing a DAPI nucleus and dextran, indicating the GAP formation (Fig. 4B and fig. S8C, white squares and arrows). Because transplanted EGFP-positive hESC-GCs did not attach the underlying lamina propria dendritic cells and immunostaining for labeling the dendritic cells was not used, the direct delivery of dextran antigen to dendritic cells was not easily observed in the present study. Nonetheless, the results indicated the GAP formation by hESC-GCs to some extent. After coculturing EGFP-positive hESC-GCs and human dendritic cells, we observed that EGFP-positive hESC-GCs took up more dextran granules than human dendritic cells (Fig. 4C). Because of lack of the intestinal epithelial barrier, the cultured dendritic cells were directly incubated in dextran-containing medium, which resulted in difficulty in observing the delivering of dextran from hESC-GCs into dendritic cells. Newberry and colleagues (5, 3743) have demonstrated that acetylcholine induces GAP formation via mAChR4 expressed by intestinal GCs and that activation of EGFR in GCs can inhibit the GAP formation. hESC-GCs and hESC were found to express mAChR4 and EGFR, evidence by RT-qPCR, immunocytochemistry, and Western blotting (Fig. 4 and fig. S8). Cultured hESC-GCs had much lower levels of EGFR activation than hESC (Fig. 4, G and J, and fig. S8, E and F), which may possibly explain why hESC-GCs could take up many dextran antigens in the culture setting. Colon GCintrinsic MYD88-dependent microbial sensing can activate EGFR and inhibit GAP formation (5). We found the mRNA expressions of the MYD88 signaling components in hESC-GCs and hESC (Fig. 4F). Bacterial infection can activate the MYD88 signaling and subsequent activation of EGFR (5). Bacterial infection increased the activation of EGFR in hESC-GCs and hESC (Fig. 4, G, I, and G, and fig. S8, E, F, and H), consistent with the increased expression of MYD88 signaling components (Fig. 4, J and L). Although bacterial infection did not induce significant changes in the mAChR4 (Fig. 4, H, I, and K, and fig. S8, G and H), bacterial infection induced the translocation of mAChR4 onto the cell membrane (Fig. 4J). Therefore, these data supported that hESC-GCs may form GAPs. On the other hand, hESC can express EGFR and mAChR4 and MYD88 signaling components, indicating that hESC in the skin surface may also form GAPs involved in the adaptive immune responses.
The relationship between gut microbiota and the host maintains the intestinal homeostasis. A disturbance of this relationship can result in intestinal disorders such as inflammatory bowel diseases and metabolic syndromes. The mucosal layer plays a critical role in maintaining a beneficial relationship between microbes and the host. The advance in research of the interaction between host and microbes has been hampered by the lack of a suitable model system recapitulating the interactions at the mucosal layer. We found that EIEC, EPEC, EHEC, and ETEC E. coli strains could adhere to hESC-GCs in monolayers and damaged the cells (Fig. 5A). When cultured in cell mass, hESC-GCs could form circular mucus droplets surrounding the edge of cells, which largely separated bacteria from cell mass (Fig. 5, B and C, and movie S2). The inner mucus layer in the colon is impervious to bacteria and protects intestinal epithelia against the lumen microbiota (18). Accordingly, the mucus droplet barrier function is like that of the inner mucus layer. It is thus hypothesized that intestinal GCs may form the inner mucus layer in the manner of mucus droplet barrier, in which many layers of droplet barriers constitute the inner mucus layer. Without the bacterial infection, hESC-GCs cultured in cell mass did not form the circular, mucus droplet barriers, supporting the idea that luminal microbiota are involved in the formation of mucus layers in the intestine (44, 45). Although the mechanism underlies the formation of circular droplets and the components in the droplets remain to be investigated, this cell-mucus droplet barrierbacteria model may be used to study how the mucus barrier can be destroyed, reconstructed, or enhanced in vitro by disturbing the bacteria and GCs.
In addition, we developed indirect coculture models of hESC-GCs and bacteria, in which mucus layers colonized by bacteria were spontaneously formed (Fig. 5D and fig. S9A). This in vitro coculture model had a membrane barrier to separate bacteria from hESC-GCs, which stimulates the separation between intestinal GCs and luminal microbiota. It will be a valuable alternative to study the fine-scale spatial organization of the gut microbial ecosystem. Moreover, the cellular model enables the study of severe gut microbiome perturbations such as antibiotic therapy or pathogen invasion, which cannot be performed in humans for obvious ethical reasons.
Without infection, it was hard for hESC-GCs cultured in DMEM/F12-based chemical induction media to form viscoelastic, gel-like mucus. However, hESC-GCs cultured in HCM could easily form viscoelastic, transparent, gel-like mucus in the absence of bacterial infection (Fig. 5E). This phenomenon implied that the culture setting had some effects on the secretory properties of hESC-GCs. HCM may possibly recapitulate the gut microenvironment better. Bacterial infection induced thick, more viscoelastic, gel-like mucus (Fig. 5F), indicating that bacterial infection could enhance the mucus secretion by hESC-GCs.
The transplantation experiments showed that some of transplanted hESC-GCs attached the denuded regions of recipient colonic epithelia, secreted mucus, and improved the repair of damaged mucus barrier to some extent. However, most of the transplanted hESC-GCs adhered to the outer mucus layer and died or were removed with feces soon. Only small number of transplanted hESC-GCs could attach the ulcerated sites of colons. Therefore, increasing the survival and decreasing the removal of hESC-GCs through feces are important for transplantation therapy. Moreover, the transplantation method used in our study could not precisely deliver hESC-GCs into the targeted lesion site. Injection of hESC-GCs under the view of the endoscope may facilitate the precise delivery of hESC-GCs to the lesion site, which will enhance the beneficial effects of hESC-GCs on recovery of colon epithelia.
We further conducted preliminary experiments to explore whether small molecules and growth factors directly could improve the recovery of colon mucus layer in the colitis model. Oral administration of chemical induction media improved the repair of the lesioned colon epithelia as compared to the control (Fig. 6G). In addition, more GCs were regenerated in the repaired colon epithelial sites. It is possible that these chemical factors may modulate the proliferation and differentiation of resident ISC into intestinal epithelial cells including GCs and subsequently contribute to the improvement of GC regeneration. Given that colon epithelia can self-heal, it is necessary to determine the relative contribution of the chemical factors to the GC regeneration in the future. Thus, an alternative colitis model (IL-10/ knockout mice) that has abnormal functions of GCs or reduced numbers of GCs may be used, instead of the DSS-induced colitis model (4). Despite IL-10/ mice used, much attention should be paid to precise evaluation of the effects of chemical recipes on GC regeneration when considering the genetic deficits on the GC differentiation, maturation, and function. In addition, further works are required to investigate which concentrations of the chemical compounds and how to deliver them provide the best effects on the regeneration of colon epithelia.
Because the chemical cocktails could promote the colon epithelial regeneration, we further examined the effects of RCBB on the intestinal ISC. We cultured adult small intestinal organoids in the ENR condition (8) and added RCBB into the ENR condition. RCBB was found to slightly inhibit proliferation of intestinal organoids and promote GC differentiation into four types of intestinal cells, especially GCs. Notably, the efficiency of RCBB-induced GC differentiation from intestinal organoids was lower than that observed during the reprogramming of hESC by RCBB (fig. S10, C and E). The differences in the effects of RCBB on hESC and ISC may be attributed to their different tissue origins. ISC have the intrinsic potential to differentiate into enterocytes, Paneth cells, and enteroendocrine cells in vivo and in vitro. By contrast, hESC derived from skin do not have the inherent potential to undergo the intestinal differentiations. Therefore, specific differentiation of ISC into GCs requires the inhibition of other cell fate commitments simultaneously, which is hard to achieve. For example, Notch signaling suppresses the secretory cell differentiation of ISC by directing enterocyte differentiation (46, 47). Thus, it is necessary to inhibit Notch signaling for efficiently inducing secretory cell differentiation from ISC (19, 46, 47). Without inhibition of Notch signaling, therefore, RCBB may not promote GC differentiation from ISC with high efficiency. However, DAPT-mediated inhibition of Notch signaling is dispensable for reprogramming of hESC into GCs by RCBB, although DAPT could slightly promote the reprogramming into GCs (fig. S7). This difference may partly contribute to the differences in the reprogramming efficiency.
In addition to the gastrointestinal tract, many organs throughout the body maintain epithelial homeostasis by forming a mucosal barrier that acts as a lubricant and helps to preserve a near-sterile epithelium. Upper and lower respiratory tract, genitourinary system, and ocular surface all have mucosal barriers secreted by GCs. Our methods of generating gut GCs provide proof of principle that a purified population of intestinal GCs can be chemically induced, and it is possible to produce other organ-specific GCs with similar methods.
In summary, we developed an efficient and rapid method to chemically induce hESC into GCs. hESC-GCs could secrete mucus, respond to mucin secretagogue signals, and deliver fluorescence antigen. In addition, several E. coli strains can adhere to hESC-GCs, and hESC-GC cell mass can form a mucus droplet barrier against bacterial infection. We established indirect coculture models of bacteria and hESC-GCs for recapitulating and researching the mucus-microbe interaction. Moreover, our study revealed that transplantation of hESC-GCs and chemical compounds could provide beneficial effects on improving intestinal mucus layer, which will be helpful in the therapy of intestinal diseases.
hESC were obtained from the Otwo Biotech Inc., which isolated hESC from the newborn foreskin. hESC were grown on plates coated with collagen IV (ColIV, Sigma-Aldrich) in EpiLife medium (Invitrogen, #MEPI500CA) supplemented with 0.06 mM Ca2+, 1% Human Keratinocyte Growth Supplement (Invitrogen, #S0015), and 1% P/S (Invitrogen). Cultures were routinely maintained at 37C in a humidified atmosphere of 5% CO2 and 95% air.
hESC were plated on collagen I (Corning)coated 6-well plates (Corning), 24-well plates (Corning), or glass coverslips (15 mm). Cells were cultured in EpiLife medium until 70 to 80% confluence. The culture medium was replaced by the chemical induction medium consisting of DMEM/F12 (Invitrogen, #10565018), 0.5% N2 (Gibco, #17502048), 0.5% B27 (Gibco, #17504044), and 1% P/S, supplemented with 5 M Repsox (MedChem Express, #HY-13012), 3 M CHIR99021 (MedChem Express, #HY-10182), bFGF (10 ng/ml; PeproTech, #100-18B-50), and BMP4 (10 ng/ml; PeproTech, #120-05ET-10). The control group was treated with the basal medium containing 1% dimethyl sulfoxide in the absence of small molecules and growth factors. The chemical induction medium was refreshed every 2 days. After 6 to 8 days of induction, hESC were induced into GCs, and the induced GCs were maintained and passaged in the chemical induction medium for the following use. Other small molecules used in the study included 3 M Kenpaullone (MedChem Express, #HY-12302), 5 M A83-01 (MedChem Express, #HY-10432), and 5 M SB431542 (Selleck, #S1067), and 5 M DAPT (MedChem Express, HY-13027).
For immunocytochemical staining, cells plated on glass coverslips were fixed with 4% paraformaldehyde or Carnoys solution (60% ethanol, 30% chloroform, and 10% glacial acetic acid) at room temperature. Cells were washed three times with PBS with Tween 20 (PBST) and incubated in blocking buffer (5% goat serum, 1% bovine serum albumin, and 0.5% Triton X-100) for 30 min at room temperature. Cells were then incubated with primary antibodies at 4C overnight and washed three times with PBST and then incubated with appropriate fluorescent probeconjugated secondary antibodies for 1 hour at room temperature. Cell nuclei were counterstained with DAPI. Images were captured with a fluorescence microscope (Olympus) or Leica Sp8 confocal microscope. The following primary antibodies were used: mouse anti-MUC2 (1:50; Santa Cruz Biotechnology), rabbit anti-MUC2 (1:100; Abcam), UEA-1 conjugated with fluorescein isothiocyanate (1:500; Sigma-Aldrich), mouse anti-TFF3 (1:100; Santa Cruz Biotechnology), rabbit anti-AGR2 (1:200; Abcam), rabbit anti-RELM (1:200; Bioss), mouse anti-CYP3A4 (1:100; Santa Cruz Biotechnology), mouse anti-villin (1:100; Santa Cruz Biotechnology), mouse anti-ChrA (1:100; Santa Cruz Biotechnology), mouse antiE-cad (1:200; Cell Signaling Technology), rabbit antiE-cad (1:200; Invitrogen), rabbit anti-CK18 (1:200; Abcam), mouse anti-CK18 (1:100; Santa Cruz Biotechnology), mouse anti-CK8 (1:200; Abcam), anti-rabbit ZO1 (1:200; Abcam), anti-rabbit occludin 1 (1:200; Abcam), anti-rabbit 1-integrin, rabbit anti-CK19 (1:500; Abcam), mouse anti-CK14 (1:500; Abcam), rabbit anti-CK5 (1:500; Abcam), rabbit goat anti-KLF4 (1:200; R&D Systems), mouse anti-KLF4 (1:100; Santa Cruz Biotechnology) goat anti-GATA6 (1:200; R&D Systems), rabbit anti-GATA6 (1:200; Cell Signaling Technology), mouse anti-GATA4 (1:100; Santa Cruz Biotechnology), mouse anti-MYD88 (1:100; Santa Cruz Biotechnology), rabbit antip-EGFR (1:200; Abcam), rabbit anti-mAchR4 (1:200; Abcam), and anti-rabbit -catenin (1:200; Abcam).
The chemical induction efficiency was calculated. Briefly, 10 randomly selected visual fields were used to count cell numbers. The total number of MUC2-positive and UEA-1-positive cells was determined, and the chemical induction efficiency was calculated as the percentages of MUC2-positive cells and UEA-1-positive cells among the total DAPI-positive cells. The data are presented as the means SEM from triplicate samples.
Total RNA was extracted from indicated cell samples by using TRIzol (Invitrogen) as instructed. RNA was reverse-transcribed by using the PrimeScript RT reagent kit with a genomic DNA eraser (Takara, #RR047A). Quantitative real-time PCR involved the use of TB Green Premix Ex Taq II (Takara) in a QuantStudio Real-Time PCR system (Applied Biosystems). The relative expression levels were normalized to that of the internal control (glyceraldehyde-3-phosphate dehydrogenase). All primer sequences are in table S1.
Cells in culture were washed with PBS and lysed in radioimmunoprecipitation assay buffer, and protein concentration in the sample lysate was determined with the bicinchoninic acid (BCA) protein assay. Total lysates were separated on a 10% SDSpolyacrylamide gel electrophoresis gel electrophoresis. After transferring to a polyvinylidene difluoride membrane (Millipore), nonspecific binding was blocked with 5% milk in tris-buffered salineTween for 1 hour at room temperature. The epitope of interest was probed with the appropriate primary antibody at 4C overnight. Membranes were then incubated with appropriate secondary antibodies conjugated with horseradish peroxidase (Santa Cruz Biotechnology). Electrochemiluminescence was performed on the ChemiImager 5500 imaging system according to the manufacturers instructions (Alpha Innotech Co.). The following primary antibodies were used: rabbit anti-MUC2, rabbit antip-EGFR, rabbit anti-mAchR4, mouse anti-MYD88, rabbit anti-CK19, mouse anti CK8, rabbit anti-CK18, mouse anti-CYP3A4, mouse anti-villin, mouse anti-ChrA, rabbit anti-LYZ, rabbit anti-HNF4, rabbit anti-GATA6, mouse anti-GATA4, mouse anti-KLF4, rabbit antiGSK-3 (Cell Signaling Technology), rabbit antiphosphoGSK-3 (Ser9), and rabbit anti-actin. -Actin expression was used as the internal control. The relative intensity was determined by the ratio of the specific marker to -actin, as measured by densitometry.
Cells were fixed in 4% paraformaldehyde or Carnoys solution for 10 min and stained with a PAS staining kit (Sigma-Aldrich), AB (Sigma-Aldrich), and AB-PAS staining kit (Solarbio) according to the manufacturers instructions.
Cell samples were fixed with 2.5% glutaraldehyde in PBS and postfixed with 1.0% osmium tetroxide in the same buffer, followed by dehydration with a graded series of ethanol. Next, cells were treated with propyleneoxide and then embedded in epoxy resin and sectioned. The ultrathin sections were contrasted with ethanolic uranyl acetate and lead citrate and observed under a transmission electron microscope (JEOL JEM-1210, Japan).
hESC-GCs were treated with 1 mM cholinergic agent CCh (Sigma-Aldrich) or PCSK (20 g/ml) (Santa Cruz Biotechnology) for 2 hours, followed by analysis of PAS assay of mucin contents in cell lysates and culture media and RT-qPCR analysis of MUC2 mRNA expression levels. hESC-GCs were treated with LPS (50 g/ml) (Sigma-Aldrich) for 24 hours or IL-13 (50 ng/ml) (PeproTech) for 1 and 3 days before RT-qPCR analysis of gene expression changes.
hESC-GCs treated with CCh or PCSK were disrupted in PBS using sonication (Sonics VCX105, USA) to obtain soluble proteins. Protein concentration was measured with a BCA protein assay kit. All proteins from different groups were diluted to the same concentration. The method to measure the mucus glycoprotein was previously described (48, 49). Briefly, cellular soluble fractions and culture media from different groups were first incubated with 0.1% periodic acid (Sigma-Aldrich) for 2 hours at room temperature, followed by the addition of the Schiff reagent (Sigma-Aldrich) and further incubation for 30 min at room temperature. The optical density value of the resulting solutions was taken at 550-nm wavelength as a measure of the amount of PAS-positive contents. Data were expressed as the fold change relative to the mean value of the control group.
hESC-GCs were seeded onto the Transwell system coated with collagen I and grown to confluence in the chemical induction medium. Once confluent, the culture medium in the upper chamber was removed, establishing the transition to an ALI culture condition. After 1 week of ALI culture, the mucus secreted in the upper chamber was collected and measured.
hESC before chemical induction and hESC-GCs were transduced with pLenti-CMV-EGFP-3FLAG vectors to express EGFP. As a result, hESC-GCs were labeled with fluorescent EGFP. For modeling antigen deliver in vitro, EGFP-positive hESC-GCs were cultured in the upper chamber of the Transwell. RB-dextran (10 kDa; Sigma-Aldrich) as a model antigen was added onto the upper chamber at 0.1 mg/ml. After incubation of 2 hours before imaging, Hoechst 33342 was added for nuclear staining. Confocal z-stacks were taken to analyze the distribution of the RB-dextran using the Leica TCS SP-8 microscope. In addition, EGFP-positive hESC-GCs were cocultured with human dendritic cells (obtained from ScienCell) on the collagen Icoated glass coverslips. After incubation with RB-dextran and Hoechst 33342, cells were imaged by the Leica TCS SP-8 microscope.
For modeling antigen delivery in vivo, adult C57BL/6 mice were administered 3% DSS for 5 days to induce colitis. Before 2 days of transplantation, mice were intraperitoneally injected with cyclosporin A (50 mg/kg) to suppress immune rejection. After 2 days of transplantation of EGFP-positive hESC-GCs into the small intestine and colon, lysine-fixable RB-dextran (2 mg/ml; Invitrogen, D1817) was injected into the desired small intestine and colon [100 l for each intestinal area with a 28G insulin syringe, which was described previously (50)]. The normal mice without DSS treatment and cell transplantation were also injected with RB-dextran into the desired segments of the small intestine and colon. After incubation of 30 min, mice were euthanized, and the regions where dextran was injected were collected. The following tissue processing method was according to the previous method with some modifications (50). The collected segments were fixed in 10% formalin solution at room temperature for 30 min and further fixed by Carnoys solution for 4 hours. The segments were followed by incubation in methanol for 2 30 min, in ethanol for 2 20 min, in xylene for 2 25 min, and in liquid paraffin for 2 30 min before paraffin embedding. After paraffin embedding, 6-m intestinal sections were incubated with DAPI to stain the nuclei. The section slides were imaged by the Leica TCS SP-8 microscope.
hESC-GCs and hESC were cultured in a 60-mm petri dish and coverslips. The experimental hESC-GCs and hESC were infected with EIEC E. coli, and the control hESC-GCs and hESC were not infected, respectively. Followed 1 day of injection, all the cell groups were performed for RT-qPCR, Western blotting, and immunostaining analyses of the EGFR, mAchR4, and MYD88 signaling components.
Bacterial adherence assays were performed according to the previous studies (51). Briefly, HeLa cells and hESC-GCs were cultured on collagen-coated coverslips in 24-well plates in monolayers. After washes with antibiotic-free medium, cells were incubated with 0.5 ml of the indicated E. coli straincontaining media (109 colony-forming units/ml) for 1 hour in a 37C, 5% CO2 incubator. Then, the bacteria-containing media were removed and washed three times with fresh media to remove nonadherent bacteria and cultured in bacteria-free media for 3 hours. The cells were then washed five times with ice-cold PBS to remove nonadherent bacteria further and fixed in cold methanol and stained in 2.5% crystal violet.
hESC-GCs were cultured on the collagen-coated coverslips in cell mass and infected with the indicated E. coli strains, respectively. After 1 to 2 days of culture, circular, bright mucus droplets were imaged and videoed.
hESC-GCs were cultured in the upper chamber of the 12-well Transwell plates or 6-well Transwell plates (Corning). In the lower chamber of Transwell, E. coli or Staphylococcus was added. After 3 to 4 days, the mucus layers were formed and collected for PAS, AB, and crystal violet staining. In another indirect coculture system, hESC-GCs were seeded on the collagen-coated 24-well plates and covered with glass coverslips. Bacteria were added to the culture medium. After 3 to 4 days, the mucus layers were formed and collected for analysis.
hESC-GCs were cultured in HCM (Lonza, CC-3198) supplemented with RCBB. Within 2 to 3 days, the culture medium was changed into viscoelastic, gel-like mucus. The gel-like mucus was collected and fixed by Carnoys solution. After fixation, the thin gel was performed for PAS, AB, AB-PAS, and UEA-1 staining. In addition, hESC-GCs cultured in HCM were infected with the indicated E. coli strain. After 1 to 2 days of infection, the culture medium was changed into more viscoelastic, gel-like mucus containing many bacteria. After fixation with Carnoys solution, the thick gel was analyzed by the PAS, AB, AB-PAS, UEA-1, and crystal violet staining.
All animal experimental procedures in this study were performed in accordance with the recommendations of the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and approved by the Animal Experimentation Ethics Committee of the Fourth Medical Center of PLA General Hospital. Female NSG mice (the immunodeficient strain) aged 8 weeks old and female C57BL/6J mice aged 8 weeks old were purchased from the SPF (Beijing) Biotechnology Co., Ltd. Transplantation of hESC-GCs was performed as described on days 7 and 10 following the initiation of DSS-induced colonic injury (52, 53). Acute colitis was induced by feeding adult female NSG mice and C57BL/6J mice with 3.0% DSS (molecular weight, 40,000) dissolved in drinking water for 5 days.
For transplantation of EGFP-positive hESC-GCs into the distal colon of the NSG mice, EGFP-positive hESC-GCs were released from the collagen-coated plates and mechanically dissociated into small sheets of epithelial tissue. Cell fragments of 500 to 1000 EGFP-positive hESC-GCs were resuspended in 200 l of diluted Matrigel (1:20) in PBS, which were anally instilled into the colonic lumen of each recipient mouse by using a syringe and a thin, flexible catheter 4 cm in length and 2 mm in diameter (n = 10 per group). After infusion, the anal verge was glued for 12 hours to prevent luminal contents from being excreted immediately. After the procedure, mice were maintained as usual. Mice were euthanized and analyzed after 7 days of transplantation.
For chemical treatment, the above chemical induction medium containing RCBB was orally administered into the C57BL/6J mice with colitis (n = 8 per group). The control group was administered with the basal medium without RCBB (n = 8 per group). After 14 days of administration, both groups were euthanized, and colon samples were collected for histological and immunohistochemical analyses.
For transplantation experiments, whole distal colons of recipients and their fluorescence were imaged using a fluorescence microscope equipped with the phase-contrast setting. In some experiments, engrafted cells were imaged with a fluorescent stereomicroscope system. For experiments of chemical treatment, whole colons were collected for analysis. For histology and immunohistochemistry, colon tissues were fixed with Carnoys solution for 4 hours, and then samples were incubated in 2 30 min in methanol, 2 20 min in ethanol, 2 25 min in xylene, and 2 30 min in liquid paraffin before paraffin embedding. Colon sections (4 to 6 m) were subjected to conventional H&E stain, PAS, AB, AB-PAS staining, and immunohistochemistry for MUC2 and UEA-1.
We then investigated the effects of the RCBB chemical cocktail on the proliferation and differentiation of mouse ISC. Proximal small intestinal crypts were isolated from adult C57BL/6J mice as previously described (8). Isolated crypts were embedded in Matrigel (growth factor reduced, Corning). The basal DMEM/F12 medium supplemented with 1% N2, 1% B27, 1 mM N-acetylcysteine (MedChem Express), and 1% P/S was added, containing the ENR growth factors including EGF (50 ng/ml; PeproTech), Noggin (100 ng/ml; PeproTech), and R-spondin 1 (500 ng/ml; PeproTech). To investigate the effects of the RCBB cocktail on the crypts, passaged intestinal crypts were first cultured under ENR condition for 4 days and then replaced with ENR + RCBB. After 4 days of chemical induction, crypts were fixed, and fixed cells were used for alkaline phosphatase assay and PAS staining and immunostained for the intestinal cell markers CYP3A4, LYZ, and ChrA and the proliferation marker Ki67. The images were taken by a light microscope and a confocal microscope.
All quantified data were statistically analyzed and are presented as means SEM. Statistical significance of differences between groups was determined by Students t test. *P < 0.05 was considered significant.
Acknowledgments: Funding: This study was supported, in part, by the National Nature Science Foundation of China (81830064 and 81721092), the National Key Research and Development Plan (2017YFC1103304), the CAMS Innovation Fund for Medical Sciences (CIFMS, 2019-I2M-5-059), and the Military Medical Research and Development Projects (AWS17J005, 2019-126). Author contributions: A.Z., H.Q., and X.F. conceived the idea. A.Z., H.Q., and X.F. designed the experiments and interpreted the data. A.Z., H.Q., M.S., M.T., J.M., and K.M. performed the experiments. A.Z., H.Q., and X.F. wrote the manuscript. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.
- Researchers investigate whether stem cell therapy is safe and effective for treatment-resistant bipolar disease - Newswise - April 18th, 2021
- Stem Cell and Regenerative Therapy Market: Cell Therapy Segment to Dominate Global Market - BioSpace - April 18th, 2021
- First in the nation, FDA-approved Phase II mesenchymal stem cell therapy for Parkinson's disease begins - Newswise - April 18th, 2021
- Cellino Biotech developing tech to help scale stem cell therapies - MedCity News - April 18th, 2021
- Stem cell treatment needed to fight the good fight - Victoria Lookout - April 18th, 2021
- Being bionic: the future of regenerative medicine - Toronto Star - April 18th, 2021
- Treating chronic myeloid leukemia (CML): By phase and more - Medical News Today - April 18th, 2021
- Andres Isaias Combining Innovation and Excellence - Influencive - April 18th, 2021
- A Massive New Gene Editing Project Is Out to Crush Alzheimer's - Singularity Hub - April 18th, 2021
- Antibiotic Use Prior to Allogeneic Stem Cell Transplantation May Be Linked to Graft Vs Host Disease - Hematology Advisor - April 18th, 2021
- Mucopolysaccharidosis (MPS) Treatment Market Is Rising With Post COVID-19 Impact Analysis, Development, CAGR - Global Banking And Finance Review - April 18th, 2021
- The Recovery Room: News beyond the pandemic April 16 - Medical News Today - April 18th, 2021
- The Governments Watchful Eye on Fraud Stemming from Stem Cell Therapy - JD Supra - April 4th, 2021
- Uprooting Cancer: Innovative Hydrogel Rapidly Reverts Cancer Cells Back to Cancer Stem Cells - SciTechDaily - April 4th, 2021
- Multiple sclerosis: Recent research on causes and treatments - Medical News Today - April 4th, 2021
- First CAR T-Cell Therapy for Multiple Myeloma: Abecma - Medscape - April 4th, 2021
- Vitro Biopharma Retains Leading Health Care Executive as Acting Director of Regulatory Affairs & Director - Benzinga - April 4th, 2021
- Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy - DocWire News - April 4th, 2021
- Orca-T Offers an Alternative to HSCT With Improved Patient Experience - OncLive - April 4th, 2021
- Russell Health Highlighted in the Silicon Review's '50 Leading Companies of the Year 2021' - PRNewswire - April 4th, 2021
- Gracell Biotechnologies Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy... - April 4th, 2021
- LGL Leukemia: Overview, Symptoms, and Treatment - Healthline - April 4th, 2021
- Funding the Next Generation of Cancer Therapies - Genetic Engineering & Biotechnology News - April 4th, 2021
- RenovaCare Announces Organizational Changes and Appointment of New Officers - GlobeNewswire - April 4th, 2021
- Stem Cell Therapy Market expected to reach USD 16.51 Billion by 2025 KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper - March 8th, 2021
- Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using StemSpine... - March 8th, 2021
- New Controversy for Stem Cell Therapy That Repairs Spinal Cords - The Great Courses Daily News - March 8th, 2021
- Cell Therapy for Cartilage Regeneration Gets a Boost With Hyaluronic Acid Enriched Chondrocytes in a 3D Tissue Engineering Platform - Business Wire - March 8th, 2021
- Scar-Forming Cells Switch to Producing New Neurons that Promote Functional Recovery in Mice after Spinal Cord Injury - Genetic Engineering &... - March 8th, 2021
- Moderna Hires Harvard Stem Cell Researcher Jonathan Hoggatt as Director of Hematology: What You Need to Know - Yahoo Finance - March 8th, 2021
- Stem Cell Banking Market Report 2021 | Growth and Opportunities Analysis - BioSpace - February 19th, 2021
- Global Cell Therapy Biomanufacturing Market (2020 to 2025) - Featuring Lonza Group, Merck & Novartis Among Others - ResearchAndMarkets.com -... - February 19th, 2021
- Off-the-Shelf NK Immunotherapy Is Safe and Promising in B-Cell NHL With Chemotherapy and Transplant - Targeted Oncology - February 17th, 2021
- Braunschweig Makes the Case for Earlier Use of CAR T-Cell Therapy in DLBCL - OncLive - February 17th, 2021
- Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection using ImmCelz - PRNewswire - February 17th, 2021
- Lineage to Host Virtual OPC1 Investor & Analyst Day on February 22, 2021 - Business Wire - February 17th, 2021
- Novartis, Gates Foundation pursue a simpler gene therapy for sickle cell - STAT - February 17th, 2021
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results - GlobeNewswire - February 17th, 2021
- Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation... - February 14th, 2021
- Zebrafish reveal regenerative protein that could inspire new treatments for muscle-wasting diseases and aging - FierceBiotech - February 11th, 2021
- Stem cell study illuminates the cause of an inherited heart disorder | Penn Today - Penn Today - February 11th, 2021
- Neurons from patient blood cells enable researchers to test treatments for genetic brain disease - Brown University - February 11th, 2021
- Therapeutic Solutions International Acquires Stem Cell Therapy That Successfully Completed FDA Double Blind Placebo Controlled Efficacy Study for Lung... - February 11th, 2021
- The Role and Activation Mechanism of TAZ in Hierarchical Microgroove/N | IJN - Dove Medical Press - February 11th, 2021
- Stem Cell Therapy Market: Top 5 trends fueling the industry revenue through 2025 - BioSpace - February 9th, 2021
- Magenta Therapeutics to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobilization Program and Preclinical Updates on Targeting Conditioning... - February 9th, 2021
- Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 2021 TCT Meetings of... - February 9th, 2021
- Creative Medical Technology Holdings Recruits Internationally Renowned Kidney Expert to Scientific Advisory Board - PRNewswire - February 9th, 2021
- Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with... - February 9th, 2021
- USC scientist Ya-Wen Chen receives American Lung Association grant to advance stem cell-based lung therapies - USC News - February 9th, 2021
- [Full text] Successful Use of Nivolumab in a Patient with Head and Neck Cancer Aft | OTT - Dove Medical Press - February 9th, 2021
- Responses to Liso-Cel Not Influenced by Prior Treatment With Anti-CD19 Agents in R/R Large B-Cell Lymphoma - Targeted Oncology - February 9th, 2021
- Drugs that trip cellular alarm could help clear out hibernating HIV - New Atlas - February 9th, 2021
- Leukemia in children: Symptoms, causes, treatment, outlook, and more - Medical News Today - February 6th, 2021
- Stem Cell Study Illuminates the Cause of a Devastating Inherited Heart Disorder - Newswise - February 4th, 2021
- iSpecimen expands offerings to support regenerative medicine, adding cryopreserved stem and immune cells to existing biospecimens available through... - February 4th, 2021
- CU Researchers Win Prize from National Eye Institute - CU Anschutz Today - February 4th, 2021
- Leading Urologist Doubles Down on CaverStem Regenerative Stem Cell Procedure for Treatment of Erectile Dysfunction in Men - BioSpace - January 25th, 2021
- Research Assistant - Department of Obstetrics and Gynaecology job with NATIONAL UNIVERSITY OF SINGAPORE | 239606 - Times Higher Education (THE) - December 24th, 2020
- Getting to the root of why hair goes gray - messenger-inquirer - December 24th, 2020
- How the COVID Virus Induces Inflammation, Cytokine Storm and Stress in Infected Lung Cells - SciTechDaily - December 24th, 2020
- Medicine by Design symposium highlights importance of convergence in regenerative medicine and human health - News@UofT - December 22nd, 2020
- 2020 in Neuroscience, Longevity, and AIand What's to Come - Singularity Hub - December 22nd, 2020
- Updated Findings Show Continued Efficacy for CAR T-Cell Therapy in Heavily Pretreated Myeloma - Targeted Oncology - December 14th, 2020
- Cell Isolation/ Separation Market worth $15.0 billion by 2025 - Exclusive Report by MarketsandMarkets - PRNewswire - December 14th, 2020
- Cord blood banks sell parents on promising stem cell research, but with no guarantees - The Arizona Republic - December 8th, 2020
- Procyon Technologies LLC and Novo Nordisk A/S to Collaborate on the Development of a Stem-Cell Based Therapy for Type 1 Diabetes - PRNewswire - December 8th, 2020
- Genetic engineering transformed stem cells into working mini-livers that extended the life of mice with liver disease - The Conversation US - December 8th, 2020
- Hadassah Medical Center and Neurogenesis Announce Groundbreaking Results from a Phase 2 Study in Progressive Multiple Sclerosis treated with NG-01... - December 8th, 2020
- Worldwide Cell Culture Industry to 2025 - Featuring Thermo Fisher Scientific, Corning Incorporated and Eppendorf Among Others - GlobeNewswire - December 8th, 2020
- The cell culturemarket is projected to reach USD 33.1 billion by 2025 from USD 19.0 billion in 2020, at a CAGR of 11.8% - GlobeNewswire - December 8th, 2020
- Treatment with Investigational LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111) Results in Complete Elimination of SCD-Related Severe... - December 8th, 2020
- New DARZALEX (daratumumab) Data from GRIFFIN Study Show Deeper and Longer Responses in Patients with Newly Diagnosed Multiple Myeloma - BioSpace - December 8th, 2020
- Anatomy of a vaccine: What it takes to create a safe, effective COVID shot - University of California - December 8th, 2020
- Development of New Stem Cell Type May Lead to Advances In Regenerative Medicine - Newswise - December 3rd, 2020
- UCLA receives $7.3 million grant to build state-of-the-art facility for developing gene, cell therapies - UCLA Newsroom - December 3rd, 2020
- Human Embryonic Stem Cells Market in Global : Current and the Future Trends: Astellas Pharma Inc/ Ocata Therapeutics, Stemcell Technologies Inc - The... - December 3rd, 2020
- Possible Role for Comprehensive Molecular ProfilingBased Treatment Selection in Newly Diagnosed AML, Study Suggests - Cancer Therapy Advisor - December 3rd, 2020
- Nobel Prize history from the year you were born - Herald & Review - December 3rd, 2020
- 4D hires a trio of area heads as it ramps up its gene therapy pipeline - FierceBiotech - December 3rd, 2020